Forging a position as an innovative player in
infectious disease vaccines and therapies

Home
About
Our Technology
Business Development
- Partner Network
- Licensing Strategy and Available Licenses
Investor Relations
Contact Us
- Corporate directory

BioDiem » » Non-renounceable pro rata Entitlement Offer

Non-renounceable pro rata Entitlement Offer June 14, 2016 • Category • Author Name

Non-renounceable pro rata Entitlement Offer

Latest News

Company Update and EOFY 2018 Information

August 3, 2018

Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following information.

Read More
Opal Information Memorandum Announcement

July 25, 2018

Opal Biosciences Limited announces its Information Memorandum

Read More

Join our email list!

Join our email distribution list to be updated with announcements.

© Copyright 2014 BioDiem

Privacy Policy
Terms and conditions